Common Reasons for Deficiency Letters in UAE Medical Device Registration: A Practical FAQ

Common Reasons for Deficiency Letters in UAE Medical Device Registration

Answer: In UAE medical device registration, dossiers most often receive correction (deficiency) notices because of incorrect product classification or the wrong regulatory pathway; technical documentation that does not match the declared model and specification matrix; weak consistency across the evidence chain (test reports, clinical evaluation, risk management and labelling claims); incomplete or inconsistent quality management system proof such as ISO 13485 certificates whose scope does not cover the submitted products; labelling and instructions for use that do not meet local language, content or claim requirements; unclear appointment of a local authorized representative or importer; and insufficient arrangements for post-market surveillance, vigilance and change maintenance. Directly translating NMPA dossiers and submitting them unchanged is another frequent trigger, because the evidence is not restructured to the format and logic expected by the UAE authority.

Key Summary

For the question “What are the common reasons for deficiency letters in UAE medical device registration?”, companies should first confirm the target country, product risk class, applicable regulatory pathway and the current documentation base, and only then assess technical files, quality system requirements, labelling and instructions for use, local agent arrangements, clinical evidence and post-market maintenance obligations. AIMEILI recommends completing a documentation gap assessment before formal submission, so that unclear classification, documentation or authorization arrangements do not extend the project timeline.

For Chinese medical device manufacturers, the more reliable approach is to complete product classification and a documentation gap assessment first, and then determine whether NMPA, CE, FDA, ISO 13485 or other market files can be reused. UAE registration typically affects technical documentation, authorized representation, importer cooperation, labelling language, quality system evidence and subsequent change maintenance at the same time. If a project is driven only by the question of “which documents to submit”, correction requests and rework are likely to arise around model coverage, evidence-chain consistency, labelling claims and control of certificates.

AIMEILI recommends positioning this question within a GHWP member state and multi-country market access strategy, using one reusable core technical file to support localization across different markets, rather than rebuilding documents on an ad hoc basis for each country.

Applicable Scenarios and Core Questions

Companies searching for this question are usually not looking for a conceptual definition. They want to judge whether their existing documentation can support a UAE submission, whether a local agent or authorized representative is required, why timelines get extended, and which issues could affect their launch plan. Behind this question there are usually several interconnected topics: product classification, registration pathway, evidence chain, labelling localization and post-market maintenance responsibilities.

If a company plans to enter several GHWP member states or markets in Southeast Asia, the Middle East and Latin America at the same time, answering the procedure for one country alone is not enough. A more valuable approach is to first develop reusable versions of the core technical file, quality system evidence, performance verification, clinical evidence and labelling and instructions for use, and then localize them according to each country’s regulatory requirements.

Registration Decision Logic

Companies should first confirm the intended use, mechanism of action, use environment, method and duration of body contact, whether the device is sterile or active, and whether it contains software or has IVD characteristics. Risk class and submission pathway can then be determined. If the pathway is wrong from the outset, all downstream translation, notarization, authorization, testing and supplementary documentation will move in the wrong direction.

For a UAE project, the applicant entity and the boundaries of local responsibility must also be confirmed: who holds the certificate, who is responsible for regulatory communication, who handles import and post-market events, who triggers changes, and who maintains renewal documentation. If these matters are only handled vaguely in a commercial contract, control over the market can be affected later.

Documentation and Evidence

Typical documentation includes the product description, model and specification matrix, intended use, risk classification rationale, ISO 13485 or applicable quality system evidence, technical file, performance verification reports, risk management file, clinical evaluation or clinical evidence, labelling and instructions for use, authorization documents, existing registration certificates, manufacturer declarations and post-market surveillance documentation.

The key to documentation quality is not volume but consistency. Labelling claims, the models covered by test reports, the applicable scope of clinical evidence, risk management conclusions, label warnings and the information in the registration application form must support each other. Regulators focus on whether the device is safe, effective and traceable for its intended use, not on how many documents have been uploaded.

Common Errors

The most common mistake is treating registration as a simple document submission without first clarifying product classification, evidence coverage and local responsibility relationships.

• Submitting directly translated NMPA documents without restructuring the evidence according to the UAE pathway.
• Declaring too many models and specifications while test reports, clinical evidence or labelling do not cover them adequately.
• Selecting a local agent purely on the basis of sales cooperation, without defining regulatory responsibility, certificate control or post-market maintenance duties.
• Inconsistency between labels, instructions for use, promotional materials and the claims made in the registration dossier, leading to correction requests or post-market compliance risk.
• Failing to plan for multi-country document reuse in advance, which multiplies cost and timelines because each country requires separate preparation.

Company Preparation Checklist

Before starting a project, companies should use an internal checklist to confirm the documentation base, so that critical evidence gaps are not discovered only after submission.

• Compile the target product list, model and specification matrix, and intended use statements.
• Verify whether existing NMPA, CE, FDA or other market registration documents can be reused.
• Prepare ISO 13485 certificates, test reports, risk management documentation, clinical evaluation and English instructions for use.
• Confirm the responsibilities, fees, certificate control and exit mechanisms of the local agent or authorized representative.
• Establish a target-country gap assessment table identifying what must be retested, translated, notarized or supported by additional declarations.

AIMEILI’s View

AIMEILI advises companies not to treat UAE registration as a one-off document submission, but to manage it as an overseas market access project. For companies entering several countries, building a clear core technical file and evidence matrix first and then converting it according to each country’s requirements is usually faster and more stable than filling documentation gaps country by country, and it also supports later changes and renewals more effectively.

From a project management perspective, three items should be controlled early: first, product classification and pathway determination; second, consistency of the documentation evidence chain; third, the regulatory responsibility boundaries of local partners. If these three items remain unclear, a project may still encounter repeated issues during correction, agent communication and post-market maintenance, even if the documentation appears extensive.

Common Follow-up Questions

Can Chinese domestic documents be used directly for UAE registration?

Domestic documents can serve as a basis, but they generally cannot be submitted as they are. Companies need to adjust the document structure, language, labelling, authorization documents and evidence chain according to local regulatory requirements.

When is the best time to start a gap assessment?

It is advisable to start immediately after the target market and product list are confirmed. The earlier the gap assessment is completed, the easier it is to arrange additional testing, translation, labelling adjustments and agent selection in advance.

Why does the choice of local agent affect registration quality?

The local agent typically participates in registration communication, changes, renewals and post-market event handling. Unclear responsibilities can affect certificate control and subsequent market stability.

Implementation Recommendations

When executing this type of registration project, companies should maintain a project register that tracks the product list, models and specifications, registration pathway, document owners, translation status, testing status, local agent communication records and expected submission dates in a single table. This makes documentation gaps visible in good time and helps management judge whether the project will affect the launch plan.

Companies that already hold registrations in several countries should also build an evidence reuse matrix, defining which documents can serve as core evidence and which must be reissued or supplemented according to national requirements. Labelling and instructions for use, clinical evaluation, risk management, performance verification and quality system certificates in particular must remain version-consistent.

• Confirm the target market and product list.
• Complete risk classification and pathway determination.
• Establish a documentation gap assessment table.
• Clarify the local agent and certificate control.
• Track translation, notarization, testing and correction status.
• Assign post-market maintenance responsibilities in advance.

Quality System and Evidence Consistency

From a registration review perspective, quality system documentation is not an isolated certificate. Regulators typically check whether the manufacturer name, manufacturing address, product scope, certificate validity period, applicable standards and technical file are consistent with each other. If the scope of the ISO 13485 certificate does not match the submitted products, or if the manufacturing address, models and specifications, or instructions for use version do not align with the test reports, additional clarification may be requested even when a large volume of documentation has been prepared.

Before submission, companies should create an evidence consistency checklist that maps product name, model and specification, intended use, applicable standards, test report numbers, clinical evaluation conclusions, risk management version, labelling and instructions for use version, and quality system certificate item by item. This step appears basic, but it significantly reduces the probability of correction requests, especially for projects submitted simultaneously to several GHWP member states or covering multiple product families.

Localization Conversion and Authorized Representative Responsibilities

UAE registration projects usually involve arrangements for a local agent, authorized representative, importer or registration holder. Companies must confirm in advance whether the local partner is only responsible for submitting documents, or also for regulatory communication, certificate maintenance, post-market event reporting, change applications and renewal reminders. Different responsibility boundaries directly affect certificate control and subsequent market stability.

Labelling, instructions for use and authorization documents also cannot simply be translated. Companies should verify local language requirements, the boundaries of product claims, warnings, storage and transport conditions, UDI or traceability requirements, importer information, authorized representative information and after-sales contact details. For companies that already hold CE, FDA, NMPA or other market documentation, the focus of localization conversion is to transform reusable evidence into a submission structure acceptable to the target country, rather than writing a separate set of isolated documents.

Post-Market Maintenance and Long-Term Planning

Registration approval does not mean the compliance work is finished. Companies also need to maintain certificate validity, change records, distributor authorizations, complaint handling, adverse event reporting, recall procedures, labelling versions and regulatory update records. Many companies invest heavily in obtaining the certificate but neglect post-market maintenance, so that a change of manufacturing address, an expansion of models, an update to the instructions for use or a replacement of the agent later causes the certificate and market sales to become misaligned.

AIMEILI recommends managing this question within an annual international registration plan: first define target market priorities, then build a reusable documentation package and a country gap list, and finally schedule submission, correction, post-market maintenance and renewal milestones. The value of this approach is not only improved efficiency in a single country, but also the development of a repeatable overseas compliance capability that reduces the cost of starting from scratch each time a new market is entered.

Content Review and Scope of Application

Content author: AIMEILI Regulatory Editorial Team. Professional review: AIMEILI Medical Device International Registration Project Team.

Source principle: priority is given to official regulatory authorities, international organizations, standards bodies and publicly available regulatory materials; industry media and project experience are used only as supporting references.

Scope of application: this article is intended for preliminary understanding, documentation preparation and project planning. It does not replace the formal requirements of the target country’s regulatory authority, testing conclusions or legal advice.